Search Results for “Novartis” – Page 26 – media

GSK reports Q1 sales decline

GlaxoSmithKline has booked a 2 percent dip in revenues for the first quarter to £7.2 billion, after results were hit by a “significant currency impact” and lower sales of prescription drugs. Profit after tax fell 38 percent to £759 million, while earnings per share dropped to 11.2p from 21.4p a year ago.
- Source: pharmatimes
- 494
- April 28, 2018
Company Insights GSK
CAR-T therapy could be available to NHS patients this year

NHS England chief executive Simon Stevens has indicated that chimeric antigen receptor T-cell therapy (CAR-T) could be available on the NHS this year, offering eligible patients a ‘ground-breaking’ approach to treating cancer.
- Source: pharmatimes
- 5,100
- April 28, 2018
cancer NHS T cell therapy
Third Rock Ventures Launches Cedilla Therapeutics with $56 Million Investment to Target Protein Stability Using Small Molecule Therapeutics

Company is targeting upstream aspects of native protein degradation pathways to develop new therapies for cancer
- Source: drugdu
- 703
- April 26, 2018
Market Views Series small molecule
ResearchKit Study to Test Smartphones’ mHealth Value in Eye Studies

Novartis is launching an mHealth app on Apple's ResearchKit platform to determine whether smartphones are reliable enough for use in ophthalmology studies.
- Source: mHealth Intelligence
- 655
- April 26, 2018
mHealth Researches
NEJM editorial slams design of GSK’s pivotal trial of 3-in-1 COPD drug Trelegy

GSK is shifting resources towards key therapeutic classes, including respiratory disease.
- Source: fiercepharma.
- 599
- April 24, 2018
Company Insight GSK respiratory disease Trelegy Ellipta
Amgen Presents First-Of-Its-Kind Data At AAN Annual Meeting Reinforcing Robust And Consistent Efficacy Of Aimovig™ (erenumab) For Migraine Patients With Multiple Treatment Failures

The LIBERTY Trial was Conducted in Patients who Have Tried Two to Four Therapies Without Success -- a Uniquely Difficult-to-Treat Population Often Excluded From Migraine Prevention Trials Patients Taking Aimovig had Nearly Three-Fold Higher Odds of Having Their Migraine Days cut by Half or More Compared to Placebo Safety and Tolerability Were Consistent With Results Seen in the Pivotal Clinical Program; Over 97 Percent of Those Taking Aimovig Completed the Double-Blind Treatment Phase Data Selected by the American Academy of Neurology Science Committee as one of the Most Noteworthy Presentations at 2018 Annual Meeting
- Source: prnewswire
- 640
- April 20, 2018
Amgen migraine
Magenta bags $52M Series C for bone marrow transplant pipeline

High-flying Cambridge startup Magenta has snagged $52 million in a new financing round to push forward the company’s pipeline of therapies for bone marrow transplant.
- Source: Endpts
- 477
- April 13, 2018
financing Market Views
Sanofi’s PD-1 inhibitor starts EU review for skin cancer

The EMA has kicked off its review of Sanofi and Regeneron’s immuno-oncology drug cemiplimab, which is aiming to become the sixth drug in the PD-1/PD-L1 inhibitor class to reach the market.
- Source: Pmlive
- 552
- April 8, 2018
cemiplimab immuno-oncology New Approvals
Macrolide Pharmaceuticals Appoints New President and CEO Raises $20 Million in Investor Financing by Allyson English

Macrolide Pharmaceuticals, a next-generation antibiotics company developing macrolides that are first-in-class with Gram-negative activity for a broad range of multi-drug resistant bacterial infections, announced that Mahesh Karande has joined the company as President and CEO. The company is also pleased to announce the completion of a $20 million financing led by current investors Advent Life Sciences, Gurnet Point Capital, Novartis Venture Fund, Roche Venture Fund and SR One.
- Source: macrolide
- 462
- April 8, 2018
macrolide antibiotics Market Views
Improving health literacy is in pharma’s interests

Patients who understand the information provided about their health are more likely to adhere to a medicine regime and feel empowered to take steps towards healthier lifestyles. To what extent are pharma companies taking the initiative? Amanda Barrell reports.
- Source: PharmaPhorum
- 710
- March 28, 2018
Consumer Healthcare Market Views

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.